Co-Delivery of a Novel Lipidated TLR7/8 Agonist and Hemagglutinin-Based Influenza Antigen Using Silica Nanoparticles Promotes Enhanced Immune Responses.

MLA

Abdelwahab, Walid M., et al. “Co-Delivery of a Novel Lipidated TLR7/8 Agonist and Hemagglutinin-Based Influenza Antigen Using Silica Nanoparticles Promotes Enhanced Immune Responses.” Pharmaceutics, vol. 16, no. 1, Jan. 2024, p. 107. EBSCOhost, https://doi.org/10.3390/pharmaceutics16010107.

APA

Abdelwahab, W. M., Auclair, S., Borgogna, T., Siram, K., Riffey, A., Bazin, H. G., Cottam, H. B., Hayashi, T., Evans, J. T., & Burkhart, D. J. (2024). Co-Delivery of a Novel Lipidated TLR7/8 Agonist and Hemagglutinin-Based Influenza Antigen Using Silica Nanoparticles Promotes Enhanced Immune Responses. Pharmaceutics, 16(1), 107. https://doi.org/10.3390/pharmaceutics16010107

Chicago

Abdelwahab, Walid M., Sarah Auclair, Timothy Borgogna, Karthik Siram, Alexander Riffey, Hélène G. Bazin, Howard B. Cottam, Tomoko Hayashi, Jay T. Evans, and David J. Burkhart. 2024. “Co-Delivery of a Novel Lipidated TLR7/8 Agonist and Hemagglutinin-Based Influenza Antigen Using Silica Nanoparticles Promotes Enhanced Immune Responses.” Pharmaceutics 16 (1): 107. doi:10.3390/pharmaceutics16010107.